Format

Send to

Choose Destination
Oncotarget. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413. eCollection 2018 Nov 30.

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management.

Author information

1
Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.

KEYWORDS:

HER2/neu; USC; endometrial cancer; trastuzumab; uterine serous carcinoma

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center